Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.78 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | SHBG | P04278 | 5/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.78 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.78 |
| ▸ | PGR | P06401 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.78 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.67 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 8/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL8570579 | 0.94 | HIF1A (0.78) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL5665147 | 0.93 | HIF1A (0.68) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Prednisolone SCHEMBL7067399 | 0.91 | HIF1A (0.71) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL2330383 | 0.91 | HIF1A (0.82) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Cortisone SCHEMBL5663871 | 0.89 | HSD17B10 (0.69) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL8164979 | 0.88 | HIF1A (0.96) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL24900238 | 0.88 | HIF1A (1.00) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL143923 | 0.88 | HIF1A (1.00) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL6932400 | 0.88 | HIF1A (1.00) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 | |
| Hydrocortisone SCHEMBL1560948 | 0.88 | HIF1A (1.00) | HIF1ASMN1; SMN2CYP3A4HSD17B10SERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3506926-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Flagship Pioneering Innovations V, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3490542-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3490581-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018022668-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022666-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2018022664-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20040115629-A1 | Comprises nucleotide sequences coding polypeptide for treament of parkinson's, alzheimer's and cancer disorders; gene therapy | PANZER SCOTT R (US) | 2004-06-17 | — | — | US | disclosed |
| EP-0340878-B1 | Process for the biochemical oxidation of steroids and genetically engineered cells to be used therefor | AVENTIS PHARMA SA (FR) | 2001-05-16 | — | — | EP | disclosed |
| EP-0481443-B1 | Transdermal therapeutic compositions | VECTORPHARMA INT (IT) | 1997-05-28 | — | — | EP | disclosed |
| US-5582836-A | RIGID SUPPORTING SHEET WITH POLYMERIC FILM MATRIX SUSPENSION CONTAINING POROUS PARTICLES LOADED WITH DRUGS AND ABSORPTION PROMOTERS | VECTORPHARMA INTERNATIONAL S.P.A. (IT) | 1996-12-10 | — | — | US | disclosed |
| EP-0481443-A1 | Transdermal therapeutic compositions | VECTORPHARMA INTERNATIONAL S.P.A. (IT) | 1992-04-22 | — | — | EP | disclosed |
| EP-0381747-A4 | WATER SOLUBLE BRANCHED BETA CYCLODEXTRIN STEROID COMPLEX | — | 1991-09-11 | — | — | EP | disclosed |
| EP-0381747-A1 | WATER SOLUBLE BRANCHED BETA CYCLODEXTRIN STEROID COMPLEX | AMERICAN MAIZE-PRODUCTS COMPANY (US) | 1990-08-16 | — | — | EP | disclosed |
| WO-1990003428-A1 | PROCESS FOR THE MULTIPLE OXIDATION OF STEROIDS AND GENETICALLY ENGINEERED CELLS TO BE USED THEREFOR | GIST-BROCADES N.V. (NL) | 1990-04-05 | — | — | WO | disclosed |
| EP-0360361-A1 | Process for the multiple oxidation of steroids and genetically engineered cells to be used therefor | ROUSSEL-UCLAF (FR) | 1990-03-28 | — | — | EP | disclosed |
| WO-1990001320-A1 | WATER SOLUBLE BRANCHED BETA CYCLODEXTRIN STEROID COMPLEX | AMERICAN MAIZE-PRODUCTS COMPANY (US) | 1990-02-22 | — | — | WO | disclosed |
| WO-1989010963-A1 | PROCESS FOR THE BIOCHEMICAL OXIDATION OF STEROIDS AND GENETICALLY ENGINEERED CELLS TO BE USED THEREFOR | GIST-BROCADES N.V. (NL) | 1989-11-16 | — | — | WO | disclosed |
| EP-0340878-A1 | Process for the biochemical oxidation of steroids and genetically engineered cells to be used therefor | ROUSSEL UCLAF (FR) | 1989-11-08 | — | — | EP | disclosed |